Researchers discover a missing link in the progression of B cell lymphoma.
Diffuse large B cell lymphoma is the most common form of non-Hodgkin lymphoma (NHL), contributing to about 30% of the cases in the United States. It is an aggressive form of NHL that usually presents itself with severe swelling of the lymph nodes at the sites being affected. The most common therapy for the disease is a combined immunotherapy with rituximab and radiotherapy. Secondary therapies are also used for patients who do not respond to the initial therapy, or who relapse after a period of remission.1